Welcome to our dedicated page for Organon & Co. news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on Organon & Co. stock.
Organon & Co. (OGN) is a science-based global pharmaceutical company dedicated to developing and delivering essential health solutions. Founded in Oss, the Netherlands, Organon originally gained fame for pioneering the birth control pill, which revolutionized women's health. Over the years, the company expanded significantly and was acquired by Schering-Plough, and later by Merck, continuing its legacy as MSD in the Netherlands.
Today, Organon operates with a robust portfolio comprising women's health, biosimilars, and established medicines. The company focuses on providing prescription therapies that address a wide range of health needs, particularly in women's health. Organon's product offerings include innovations in contraception, fertility treatments, and menopause management.
In addition to women's health, Organon is committed to advancing the field of biosimilars - biologically similar products to existing branded drugs that promise to enhance patient access to key treatments. The company's established brands, which include a variety of well-known medications, continue to be a core revenue driver. Geographically, Organon derives most of its revenue from Europe and Canada, followed by the United States, and then the Asia Pacific and Japan regions.
Organon remains at the forefront of pharmaceutical innovation, driven by a mission to improve health outcomes globally. The company's strategic partnerships and continued investment in research and development reflect its commitment to addressing some of the most pressing health challenges of our time.
Organon (NYSE: OGN) reported full-year 2022 revenues of $6.2 billion, a 2% decrease from 2021. Women's Health revenue grew 4% to $1.7 billion, driven by Nexplanon, while Biosimilars increased 13% to $481 million. Established Brands experienced a 5% revenue decline to $3.9 billion.
Adjusted EBITDA was $2.1 billion with an EBITDA margin of 33.8%. The diluted earnings per share from continuing operations fell to $3.59, down 32% from 2021. For 2023, revenue guidance ranges from $6.150 billion to $6.450 billion.
Organon (NYSE: OGN) emphasizes the critical need for increased investment in women's health ahead of International Women's Day on March 8. The company highlights that only 1% of healthcare research targets conditions unique to women. As part of its commitment, Organon provides paid time off for its 10,000 employees globally, including 400 in the MENAT region, to advocate for women's health. Key areas of concern include menopause, maternal health, and endometriosis, with calls to engage stakeholders in addressing these issues. Organon aims to stimulate dialogue and action to improve women's health outcomes.
Organon (NYSE: OGN), a global women’s healthcare company, will announce its fourth quarter and full year 2022 financial results on February 16, 2023, before its conference call at 8:30 a.m. EST. The call will be accessible via a live webcast on the Organon website, with a replay available two hours post-event. Institutional investors must register in advance to participate, allowing them to join without operator assistance. Organon focuses on women's health, featuring over 60 products, and is positioned for growth through collaboration with biopharmaceutical innovators in international markets.
Organon (NYSE: OGN) has announced an $8 million strategic investment in Claria Medical, a company developing a medical device aimed at enhancing laparoscopic hysterectomy procedures. This investment includes an option for Organon to acquire Claria Medical. The Claria System is designed to improve safety and efficiency in hysterectomy surgeries and has been accepted into the FDA’s Safer Technologies Program. This move underscores Organon’s commitment to innovation in women’s healthcare.
Organon (NYSE: OGN) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10th, 2023, at 7:30 a.m. PT. CEO
Organon (NYSE: OGN) announced the appointment of Kirke Weaver as General Counsel and Corporate Secretary, effective January 1, 2023. Mr. Weaver, who was previously the interim head since July 2022, brings nearly 20 years of pharmaceutical experience, including key roles at Merck. His leadership is expected to further Organon's commitment to women’s health while enhancing its ethical operations. The company aims for continued growth through innovation and collaboration in the healthcare sector.
Organon (NYSE: OGN) will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 9:00 a.m. EST. The chat will feature CEO Kevin Ali and CFO Matthew Walsh. Interested parties can listen to the live webcast via this link. Organon focuses on women's health with a diverse portfolio of over 60 medicines and products, supported by a robust cash flow, aiming for innovation and growth.
Organon reported third quarter 2022 revenues of $1,537 million, a 4% decline year-over-year. Diluted EPS from continuing operations was $0.89, down 30% from the previous year. Adjusted EBITDA stood at $546 million, down 11% year-over-year, reflecting higher costs and R&D expenditures. The women's health segment grew by 19%, while established brands saw a 11% decline. The company declared a quarterly dividend of $0.28 per share. Full year revenue guidance was narrowed to $6.1 billion to $6.2 billion.
Organon (NYSE: OGN) will announce its third quarter 2022 financial results on November 3, 2022, before a conference call at 8:30 a.m. EDT. The event can be accessed via a webcast on the company’s website, with a replay available shortly after. Organon focuses on improving women’s health and has a diverse portfolio of over 60 products, supported by strong cash flows. With a significant global presence, the company aims to expand its biosimilars business and collaborate with biopharmaceutical innovators.
Samsung Bioepis and Organon announced FDA approval for HADLIMA™ (adalimumab-bwwd), a citrate-free, high-concentration formulation of the adalimumab biosimilar referencing HUMIRA®. It will be available in pre-filled syringes and autoinjectors, enhancing treatment options for patients with chronic autoimmune diseases. This high-concentration version builds on the previous approval of a 50 mg/mL formulation in July 2019. The launch is expected on or after July 1, 2023, aiming to provide a more affordable alternative to the currently high-cost adalimumab in the U.S.
FAQ
What is the current stock price of Organon & Co. (OGN)?
What is the market cap of Organon & Co. (OGN)?
What is Organon & Co. known for?
What are the main product areas of Organon & Co.?
Where does Organon & Co. generate most of its revenue?
Who previously acquired Organon & Co.?
What types of products does Organon offer in women's health?
What are biosimilars?
How does Organon & Co. contribute to global health?
Has Organon & Co. been involved in any recent significant projects or initiatives?
What is the history of Organon & Co. in the Netherlands?
What is the significance of Organon's established brands?
